The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-05 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Necrotizing fasciitis Plantar fasciitis Ischemic fasciitis, classified by the World Health Organization, 2020, as a specific tumor form in the category of fibroblastic and myofibroblastic tumors. Eosinophilic fasciitis Paraneoplastic fasciitis
== References == This article incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Chevreul, Michel Eugène". Encyclopædia Britannica (11th ed.). Cambridge University Press.
CAM plants, such as cacti and succulent plants, also use the enzyme PEP carboxylase to capture carbon dioxide, but only at night. Crassulacean acid metabolism allows plants to conduct most of their gas exchange in the cooler night-time air, sequestering carbon in 4-carbon sugars which can be released to the photosynthesizing cells during the day. This allows CAM plants to minimize water loss (transpiration) by maintaining closed stomata during the day. CAM plants usually display other water-saving characteristics, such as thick cuticles, stomata with small apertures, and typically lose around 1/3 of the amount of water per CO2 fixed.
== Pathophysiology == Myxedema describes a specific form of cutaneous and dermal edema secondary to increased deposition of connective tissue components. The connective fibres are separated by an increased amount of protein and glycosaminoglycans. This protein-mucopolysaccharide complex binds water, producing non-pitting boggy edema, in particular around eyes, hands, feet and in the supraclavicular fossae. This deposition involves not only the skin but also the tongue, myocardium, kidney medulla, lung, intestine and most other organs of the body (apart from the stomach). Myxoedema is also responsible for the thickening of the laryngeal and pharyngeal mucous membranes, which results in thick slurred speech and hoarseness, both of which are seen commonly in hypothyroidism. The accumulation of glycosaminoglycans (GAGs) in the dermal tissues consists characteristically of hyaluronic acid with very little change in the dermatan sulfate abundance and perhaps a decrease in chondroitin sulfate. The tissue change in myxedema can be related directly to the physicochemical properties of hyaluronate. Its hygroscopic nature allows it to swell to one thousand times its dry weight when hydrated. The pathogenesis of generalized myxedema is thought to be fairly well understood and related to the deficiency of thyroid hormone, but the pathogenesis of pretibial and orbital myxedema due to Graves' disease is not fully understood, however, two mechanisms predominate:
Sources: en.wikipedia.org
4 March The Rector of Saigon University, Professor Tran Anh, was shot by VC on a motorcycle; previously he had been notified that he was on the "death list" of the "Suicide Regiment of the Saigon Youth Guard."
=== Chemistry === According to chemical weapons expert Jonathan Tucker, the first binary formulation developed under the Foliant programme was used to make Substance 33 (VR), very similar to the more widely known VX, differing only in the alkyl substituents on its nitrogen and oxygen atoms. "This weapon was given the code name Novichok."
The House Foreign Affairs Committee has investigated the origins of the pandemic, and heard classified briefings. The Republican minority issued a report in August 2021 that they believed the origin of the pandemic was an accidental lab escape. The resurgence of the theory of a laboratory accident was fueled in part by the publication, in May 2021, of early emails between Anthony Fauci and scientists discussing the issue, before deliberate manipulation was ruled out as of March 2020. On 14 July 2021, the House Committee on Science, Space and Technology held the first congressional hearing on the origins of the virus. Bill Foster, an Illinois Democrat who chaired the hearing, said the Chinese government's lack of transparency is not in itself evidence of a lab leak and cautioned that answers may not be known even after the administration produces its intelligence report. Expert witnesses Stanley Perlman and David Relman presented to the congressman different proposed explanations for the origins of the virus and how to conduct further investigations. On 16 July 2021, CNN reported that Biden administration officials considered the lab leak theory "as credible" as the natural origins theory. In October 2022, an interim report of a Republican member of a US Senate committee concluded that a lab origin was most likely, but offered "little new evidence", according to The New York Times. In February 2023, the United States Energy Department updated its assessment on the origins of the virus, shifting from "undecided" to "low confidence" in favor of a laboratory leak.
Sources: en.wikipedia.org
=== 2010–2012: SODMG, Mad Decent, various mixtapes === Beginning in 2011, Riff Raff began to be managed by OG Ron C (of Swishahouse fame) and moved to Los Angeles. Riff Raff then started releasing more music videos that furthered the artist's internet fame. Those include songs such as "Jose Canseco", and "Marc Jacobs". Then in mid-2011, Riff Raff signed to Soulja Boy's label S.O.D. Money Gang Inc. Riff Raff joined Soulja Boy's SODMG label before they met in person; no paperwork was ever signed. However, Riff Raff still wore the imprint's chain, got its logo tattooed, and again adjusted his stage name, this time to Riff Raff SODMG. They would remain affiliated for around a year, but the label did not push or pay Riff Raff, which would result in him leaving the label. Soulja Boy publicly called Riff Raff a "cokehead" following their split. Some time before the official split Riff Raff affiliated with producers such as Diplo and Harry Fraud, as well as with Queens rapper Action Bronson. The music video he released for his collaboration with Fraud and Bronson, "Bird on a Wire", hit the one million plays-mark in roughly two months. "Bird on a Wire" was listed as the 27th best song of 2012 by Complex Music. In early 2012 he would release music videos for the songs, "Larry Bird", "Time" and the Chief Keef collaboration "Cuz My Gear", among others. In April 2012, Riff Raff also announced a collaborative album with Diplo tentatively titled Jody Highroller with guests Skrillex, Usher, Soulja Boy, Gucci Mane, Mystikal and Rusko.
== Treatment devices used == The insulin pump is one device used in intensive insulinotherapy. The insulin pump is about the size of a beeper. It can be programmed to send a steady stream of insulin as basal insulin. It contains a reservoir or cartridge holding several days' worth of insulin, the tiny battery-operated pump, and the computer chip that regulates how much insulin is pumped. The infusion set is a thin plastic tube with a fine needle at the end. There are also newer "pods" which do not require tubing. It carries the insulin from the pump to the infusion site beneath the skin. It sends a larger amount before eating meals as "bolus" doses. The insulin pump replaces insulin injections. This device is useful for people who regularly forget to inject themselves or for people who don't like injections. This machine does the injecting by replacing the slow-acting insulin for basal needs with an ongoing infusion of rapid-acting insulin. Basal insulin: the insulin that controls blood glucose levels between meals and overnight. It controls glucose in the fasting state. Boluses: the insulin that is released when food is eaten or to correct a high reading. Another device used in intensive insulinotherapy is the injection port. An injection port is a small disposable device, similar to the infusion set used with an insulin pump, configured to accept a syringe. Standard insulin injections are administered through the injection port.
== Clinical significance == A mutation in the tyrosinase gene resulting in impaired tyrosinase production leads to type I oculocutaneous albinism, a hereditary disorder that affects one in every 20,000 people. Tyrosinase activity is very important. If uncontrolled during the synthesis of melanin, it results in increased melanin synthesis. Decreasing tyrosinase activity has been targeted for the improvement or prevention of conditions related to the hyperpigmentation of the skin, such as melasma and age spots. Several polyphenols, including flavonoids or stilbenoid, substrate analogues, free radical scavengers, and copper chelators, have been known to inhibit tyrosinase. Henceforth, the medical and cosmetic industries are focusing research on tyrosinase inhibitors to treat skin disorders.
Meanwhile, the Central and Eastern European communist states politically deteriorated in response to the success of the Polish Solidarity movement and the possibility of Gorbachev-style political liberalisation. In 1989, revolts began across Central and Eastern Europe and China against Marxist–Leninist regimes. In China, the government refused to negotiate with student protestors, resulting in the 1989 Tiananmen Square massacre that stopped the revolts by force. The Pan-European Picnic, which was based on an idea by Otto von Habsburg to test the reaction of the Soviet Union, then triggered a peaceful chain reaction in August 1989, at the end of which there was no longer East Germany and the Iron Curtain and the Marxist–Leninist Eastern Bloc had collapsed. On the one hand, as a result of the Pan-European Picnic, the Marxist–Leninist rulers of the Eastern Bloc did not act decisively, but cracks appeared between them and on the other hand the media-informed Central and Eastern European population now noticed a steady loss of power in their governments.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.